These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6891926)

  • 1. Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).
    Gouyette A; Huertas D; Droz JP; Rouesse J; Amiel JL
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1285-92. PubMed ID: 6891926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for electrophilic properties of N2-methyl-9-hydroxy ellipticinium acetate (Celiptium) from human biliary metabolites.
    Bernadou J; Monsarrat B; Roche H; Armand JP; Paoletti C; Meunier B
    Cancer Chemother Pharmacol; 1985; 15(1):63-5. PubMed ID: 4006051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of the anti-tumour drugs N2-methyl-9-hydroxyellipticinium acetate (NSC 264137) and N2-methyl-9-hydroxyolivacinium acetate in the rat: preliminary identification of biliary 9-(O)-glucuronide and 10-(S)-glutathione conjugates.
    Maftouh M; Meunier G; Dugue B; Monsarrat B; Meunier B; Paoletti C
    Xenobiotica; 1983 May; 13(5):303-10. PubMed ID: 6636827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxidase-catalysed covalent binding of the antitumor drug 2N-methyl-9-hydroxy-ellipticine to proteins.
    Auclair C; Meunier B; Paoletti C
    Biochem Pharmacol; 1983 Dec; 32(24):3883-6. PubMed ID: 6661265
    [No Abstract]   [Full Text] [Related]  

  • 5. Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture.
    Dugue B; Auclair C; Meunier B
    Cancer Res; 1986 Aug; 46(8):3828-33. PubMed ID: 2425935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxidase-catalyzed covalent binding of the antitumor drug N2-methyl-9-hydroxyellipticinium to DNA in vitro.
    Auclair C; Dugué B; Meunier B; Paoletti C
    Biochemistry; 1986 Mar; 25(6):1240-5. PubMed ID: 3964674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile.
    Maftouh M; Monsarrat B; Rao RC; Meunier B; Paoletti C
    Drug Metab Dispos; 1984; 12(1):111-9. PubMed ID: 6141901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metabolism and pharmacokinetics of methoxy-9-ellipticine and its principal metabolite, hydroxy-9-ellipticine].
    Lecointe P; Puget A
    C R Seances Acad Sci III; 1983; 296(6):279-82. PubMed ID: 6405990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of electrochemical detection in the high-performance liquid chromatographic determination of hydroxylated ellipticine derivatives.
    Bellon P; Canal P; Bernadou J; Soula G
    J Chromatogr; 1984 Jul; 309(1):170-6. PubMed ID: 6480764
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of the 6-alkyl substitution of ellipticine on the uptake by NIH-3T3 cells and on the cytotoxicity.
    Deprés JP; Larue L; Paoletti J; Gouyette A
    Anticancer Res; 1988; 8(1):191-6. PubMed ID: 3358635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative physiological disposition of ellipticine in several animal species after intravenous administration.
    Chadwick M; Silveira DM; Platz BB; Hayes D
    Drug Metab Dispos; 1978; 6(5):528-41. PubMed ID: 30602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adducts.
    Pratviel G; Bernadou J; Ha T; Meunier G; Cros S; Meunier B; Gillet B; Guittet E
    J Med Chem; 1986 Aug; 29(8):1350-5. PubMed ID: 3090263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxidase-catalysed oxidation of N2,N6-dimethyl-9-hydroxyellipticinium acetate. Evidence for the formation of an electrophilic quinone-iminium derivative.
    Meunier G; Bernadou J; Meunier B
    Biochem Pharmacol; 1987 Aug; 36(16):2599-604. PubMed ID: 3606658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. omicron-Quinone formation in the biochemical oxidation of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.
    Bernadou J; Meunier G; Paoletti C; Meunier B
    J Med Chem; 1983 Apr; 26(4):574-9. PubMed ID: 6834391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals.
    Van-Bac N; Moisand C; Gouyette A; Muzard G; Dat-Xuong N; Le Pecq JB; Paoletti C
    Cancer Treat Rep; 1980; 64(8-9):879-87. PubMed ID: 7448826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.
    Longnecker SM; Donehower RC; Cates AE; Chen TL; Brundrett RB; Grochow LB; Ettinger DS; Colvin M
    Cancer Treat Rep; 1987 Jan; 71(1):53-9. PubMed ID: 2878719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rat biliary and urinary metabolism of the N6-methylated derivative of elliptinium acetate, and antitumor agent.
    Braham Y; Meunier G; Meunier B
    Drug Metab Dispos; 1988; 16(2):316-21. PubMed ID: 2898353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L; Grever MR; Staubus AE; Young D
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human and rat urinary metabolites of the antitumor drug Celiptium (N2-methyl-9-hydroxyellipticinium acetate, NSC 264137). Identification of cysteine conjugates supporting the "biooxidative alkylation" hypothesis.
    Monsarrat B; Maftouh M; Meunier G; Dugué B; Bernadou J; Armand JP; Picard-Fraire C; Meunier B; Paoletti C
    Biochem Pharmacol; 1983 Dec; 32(24):3887-90. PubMed ID: 6661266
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.